Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to $6.8 million.

  • UroGen Pharma's Other Non-Current Assets rose 172675.68% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 172675.68%. This contributed to the annual value of $589000.0 for FY2024, which is 7109.91% down from last year.
  • UroGen Pharma's Other Non-Current Assets amounted to $6.8 million in Q3 2025, which was up 172675.68% from $801000.0 recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Other Non-Current Assets registered a high of $6.8 million during Q3 2025, and its lowest value of $66000.0 during Q1 2021.
  • Moreover, its 5-year median value for Other Non-Current Assets was $1.6 million (2022), whereas its average is $1.8 million.
  • As far as peak fluctuations go, UroGen Pharma's Other Non-Current Assets skyrocketed by 312363.64% in 2021, and later tumbled by 8195.12% in 2024.
  • Quarter analysis of 5 years shows UroGen Pharma's Other Non-Current Assets stood at $1.3 million in 2021, then skyrocketed by 109.0% to $2.7 million in 2022, then fell by 25.62% to $2.0 million in 2023, then crashed by 71.1% to $589000.0 in 2024, then soared by 1047.54% to $6.8 million in 2025.
  • Its Other Non-Current Assets stands at $6.8 million for Q3 2025, versus $801000.0 for Q2 2025 and $371000.0 for Q1 2025.